SeqWright's Partnership With Third Wave Contributes to FDA Success
...ship established in 2004, when the two companies began work on
Third Wave's ugt1a1
Molecular Assay. SeqWright provided FDA-level
sequencing to validate the ugt1a1
pharmacogenetic test, which is used to
identify patients susceptible to adv...
Gene screen patent leads to 'Deal of Distinction'
...Chicago and the Mayo Clinic. The deal licensed the ugt1a1
diagnostic screen that predicts a patient's risk o...niversity of Chicago, and colleagues developed the ugt1a1
UChicagoTech was the sole honoree in the ...re than 5,000 patients are expected to receive the ugt1a1
test this year.
UGT1A1 in Medical Technology
DNA Test Predicts Harmful Effects of Cancer Drug
...openia if they had two
copies of a variation of the gene UGT1A1, known as UGT1A1*28. At lower
doses, however, the risk was the same regardless of what ugt1a1
patients had. "Many institutions saw the FDA's recommendation as authorization to
test all patients before treating them with irinotecan, ev...
UGT1A1 in Biological News
UNC study questions FDA genetic-screening guidelines for cancer drug
...openia if they had two copies of a variation of the gene UGT1A1, known as UGT1A1*28. At lower doses, however, the risk was the same regardless of what ugt1a1
gene the patients had.
Many institutions saw the FDAs recommendation as a mandate to test all patients before treating them with irinotecan even th...
UGT1A1 in Biological Technology
Third Wave receives FDA clearance of pharmacogenetic test
...e U.S. Food and Drug Administration (FDA) has cleared the company's Invader ugt1a1
Molecular Assay for in vitro diagnostic use.
It is the first pharmacoge...mptosar (irinotecan) by detecting and identifying specific mutations in the ugt1a1
gene that have been associated with that risk, the company reported. Campto...
Third Wave posts $22 million loss, stock rises
"During 2005, we increased our recurring clinical customer base to more than 140, and launched new clinical products, including our FDA-cleared ugt1a1
pharmacogenetic test," said CEO Kevin Conroy in a press release. "Our Invader chemistry also enables us to capture recurring-revenue opportunities in ...